z-logo
open-access-imgOpen Access
Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils
Author(s) -
Denis Dacheux,
Bertrand Toussaint,
Marceline Richard,
Guy Brochier,
J. Croizé,
Ina Attrée
Publication year - 2000
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.68.5.2916-2924.2000
Subject(s) - biology , microbiology and biotechnology , secretion , pseudomonas aeruginosa , cytotoxicity , multiplicity of infection , dna fragmentation , phagocyte , type three secretion system , cell culture , phagocytosis , in vitro , apoptosis , programmed cell death , bacteria , virulence , biochemistry , gene , genetics
Pseudomonas aeruginosa , an opportunistic pathogen responsible most notably for severe infections in cystic fibrosis (CF) patients, utilizes the type III secretion system for eukaryotic cell intoxication. The CF clinical isolate CHA shows toxicity towards human polymorphonuclear neutrophils (PMNs) which is dependent on the type III secretion system but independent of the cytotoxin ExoU. In the present study, the cytotoxicity of this strain toward human and murine macrophages was demonstrated. In low-multiplicity infections (multiplicity of infection, 10), approximately 40% of the cells die within 60 min. Analysis of CHA-infected cells by transmission electron microscopy, DNA fragmentation assay, and Hoechst staining revealed the hallmarks of oncosis: cellular and nuclear swelling, disintegration of the plasma membrane, and absence of DNA fragmentation. A panel of 29P. aeruginosa CF isolates was screened for type III system genotype, protein secretion profile, and cytotoxicity toward PMNs and macrophages. This study showed that six CF isolates were able to induce rapid ExoU-independent oncosis on phagocyte cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here